The Scottish Medicines Consortium (SMC) announced that 'Isentress'® (raltegravir) has been accepted for restricted use within NHS Scotland in combination with other antiretroviral medicinal products agents for the treatment of Human Immunodeficiency Virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
More...